Neuroscience
From Reuters:
Cyberonics falls as Senate probes FDA turnaround
Thu May 19, 2005 10:07 AM ET
CHICAGO (Reuters) - Shares of Cyberonics Inc. fell almost 13 percent on Thursday after the Senate Finance Committee began examining the FDA's handling of the company's application to use an implantable device for epilepsy to also treat chronic depression.
[ ... Read the full report ... ]
~ Earlier BrainBlog posts on this topic:
07 April 2005
04 February 2005
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...
- Business World: Cyberonics And Neurostimulators
The Houston Press, which is an alternative news weekly in Houston, has a feature article this week about Cyberonics and its epilepsy device and its exploration of applications in mood disorders: Exposed Nerve Cyberonics has implanted its pacemaker in...
- Cylert
From Reuters: Abbott Says Withdrawing Attention Deficit Drug 24 March 2005 Health - Reuters WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was...
- Vagal Nerve Stimulator And Depression
From The New York Times: F.D.A. May Approve an Implant as a Treatment for Depression By BARNABY J. FEDER The New York Times Published: February 4, 2005 The Food and Drug Administration said yesterday that it might permit an implantable electrical...
- Business World: Neuromodulation
This Canadian National Post report, among many yesterday and today, outlines ANS [company website] and Cyberonics [company website] issues: Advanced Neuromodulation Systems bids US$22 a share for Cyberonics Canadian Press (copyright) Thursday, September...
Neuroscience
Business World: Cyberonics and Neurostimulators (Vagal Nerve Stimulator [VNS])
From Reuters:
Cyberonics falls as Senate probes FDA turnaround
Thu May 19, 2005 10:07 AM ET
CHICAGO (Reuters) - Shares of Cyberonics Inc. fell almost 13 percent on Thursday after the Senate Finance Committee began examining the FDA's handling of the company's application to use an implantable device for epilepsy to also treat chronic depression.
[ ... Read the full report ... ]
07 April 2005
04 February 2005
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...
- Business World: Cyberonics And Neurostimulators
The Houston Press, which is an alternative news weekly in Houston, has a feature article this week about Cyberonics and its epilepsy device and its exploration of applications in mood disorders: Exposed Nerve Cyberonics has implanted its pacemaker in...
- Cylert
From Reuters: Abbott Says Withdrawing Attention Deficit Drug 24 March 2005 Health - Reuters WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was...
- Vagal Nerve Stimulator And Depression
From The New York Times: F.D.A. May Approve an Implant as a Treatment for Depression By BARNABY J. FEDER The New York Times Published: February 4, 2005 The Food and Drug Administration said yesterday that it might permit an implantable electrical...
- Business World: Neuromodulation
This Canadian National Post report, among many yesterday and today, outlines ANS [company website] and Cyberonics [company website] issues: Advanced Neuromodulation Systems bids US$22 a share for Cyberonics Canadian Press (copyright) Thursday, September...